About Ayatris
Ayatris helps drug developers study how therapies affect human biology. Its lab systems use human tissue and flowing liquid to model organs, diseases, drug safety, and effectiveness. Researchers can use the tools to discover drugs, move lab findings toward patient care, and tailor treatment to individual patients.
Founder and CEO Srujana Cherukuri leads the Frederick, Maryland company. Its three systems are Body-on-a-Chip, Forebrain-on-a-Chip, and Placenta-on-a-Chip. Its portfolio uses both proprietary and licensed technologies. Ayatris plans partnerships with academic institutions and government laboratories. It also plans partnerships with health care organizations and industry stakeholders.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Nov 19, 2026 | $100,000of $800K target | 1 | $100K | OptionsRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Ayatris's Form D filed Nov 19, 2026.

Why Investors Backed Ayatris
Animal studies can miss toxicity and efficacy signals that appear only in human trials, costing years and millions. Regulators now allow non-animal evidence in submissions. TEDCO funded Ayatris' plan for human-relevant research infrastructure and collaboration across Maryland. [1][2]
“This award represents a significant milestone for Ayatris and validates our vision of building next-generation platforms that better predict human biology and accelerate therapeutic innovation.”
Origin and Team
Srujana Cherukuri founded Ayatris. [2]
Product and Technology
The three systems share one vascular design. The Body-on-a-Chip uses flowing capillary networks to connect several organ types. [1]
The Forebrain-on-a-Chip uses layers and gradients to grow organized brain-like tissue structures. [1]
The Placenta-on-a-Chip combines placenta tissue grown from stem cells with fluid channels that mimic blood vessels. [1]
Use of Funds
- The award funds laboratory infrastructure at the Frederick Innovation Technology Center. The project includes chip manufacturing, human sample biobanking, and vascularized organoid work. It also includes imaging, molecular characterization, and automated workflows. [2]
Milestones
Scroll table to see all columns →
Market
Founder Srujana Cherukuri sees the industry moving toward predictive, human-centered research methods. She believes Maryland can lead that shift. [2]
We wrote this summary from public statements by Ayatris and its investors. It is not investment advice.
Sources
- CompanyAyatris platform · linked above ↑
- CompanyAyatris TEDCO award announcement
- SECAyatris Form D, filed 2026-11-19 · linked above ↑
- SECAyatris, Inc. filing history
